JP2018531251A - セルロース誘導体の等軸結晶ネットワークによる、オメガ−3を有しているエマルションの、調製方法および安定化方法 - Google Patents
セルロース誘導体の等軸結晶ネットワークによる、オメガ−3を有しているエマルションの、調製方法および安定化方法 Download PDFInfo
- Publication number
- JP2018531251A JP2018531251A JP2018517314A JP2018517314A JP2018531251A JP 2018531251 A JP2018531251 A JP 2018531251A JP 2018517314 A JP2018517314 A JP 2018517314A JP 2018517314 A JP2018517314 A JP 2018517314A JP 2018531251 A JP2018531251 A JP 2018531251A
- Authority
- JP
- Japan
- Prior art keywords
- emulsion
- oil
- hdha
- omega
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 270
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 96
- 229920002678 cellulose Polymers 0.000 title claims abstract description 56
- 239000001913 cellulose Substances 0.000 title claims abstract description 56
- 239000013078 crystal Substances 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title description 29
- 230000000087 stabilizing effect Effects 0.000 title description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 78
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 66
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 26
- 235000016709 nutrition Nutrition 0.000 claims abstract description 24
- 230000035764 nutrition Effects 0.000 claims abstract description 18
- 235000014268 sports nutrition Nutrition 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 132
- 235000019198 oils Nutrition 0.000 claims description 130
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 64
- 235000010980 cellulose Nutrition 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 52
- 239000012071 phase Substances 0.000 claims description 48
- 239000008346 aqueous phase Substances 0.000 claims description 43
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 150000003626 triacylglycerols Chemical class 0.000 claims description 26
- 239000003995 emulsifying agent Substances 0.000 claims description 22
- -1 diglycerides Chemical class 0.000 claims description 19
- 150000002632 lipids Chemical class 0.000 claims description 19
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 17
- 235000021323 fish oil Nutrition 0.000 claims description 16
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000007764 o/w emulsion Substances 0.000 claims description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 12
- 235000021588 free fatty acids Nutrition 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- HLHYXXBCQOUTGK-FHCQLJOMSA-N (7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/CCC(O)=O HLHYXXBCQOUTGK-FHCQLJOMSA-N 0.000 claims description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- MCRJLMXYVFDXLS-IHWYZUJNSA-N 12S-HEPE Natural products CC\C=C/C\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-IHWYZUJNSA-N 0.000 claims description 6
- XLYRHVKBJYDBOS-HXSPUPMESA-N 16,17-Epoxy-DHA Chemical compound CC\C=C/CC1OC1\C=C\C=C\C=C/C\C=C/C\C=C/CCC(O)=O XLYRHVKBJYDBOS-HXSPUPMESA-N 0.000 claims description 6
- SWTYBBUBEPPYCX-YTQNUIGOSA-N 17(S)-HDoHE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O SWTYBBUBEPPYCX-YTQNUIGOSA-N 0.000 claims description 6
- LRWYBGFSVUBWMO-UAAZXLHOSA-N 18(R)-HEPE Chemical compound CC[C@@H](O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O LRWYBGFSVUBWMO-UAAZXLHOSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- OIWTWACQMDFHJG-CCFUIAGSSA-N resolvin D1 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-CCFUIAGSSA-N 0.000 claims description 6
- IKFAUGXNBOBQDM-XFMPMKITSA-N resolvin D2 Chemical compound CC\C=C/C[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)C\C=C/CCC(O)=O IKFAUGXNBOBQDM-XFMPMKITSA-N 0.000 claims description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 5
- FTAGQROYQYQRHF-GHWNLOBHSA-N 5S-HEPE Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O FTAGQROYQYQRHF-GHWNLOBHSA-N 0.000 claims description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- AOPOCGPBAIARAV-OTBJXLELSA-N resolvin E1 Chemical compound CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-OTBJXLELSA-N 0.000 claims description 5
- JBRPFYYLEQERPG-XTIXYJHRSA-N resolvin d5 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C=C/[C@@H](O)\C=C/CCCC(O)=O JBRPFYYLEQERPG-XTIXYJHRSA-N 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001761 ethyl methyl cellulose Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- ZNEBXONKCYFJAF-MBRSJONVSA-N (14R)-HDoHE Chemical compound CC\C=C/C\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O ZNEBXONKCYFJAF-MBRSJONVSA-N 0.000 claims description 3
- ZNEBXONKCYFJAF-OUKOMXQNSA-N (14S)-HDoHE Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O ZNEBXONKCYFJAF-OUKOMXQNSA-N 0.000 claims description 3
- AOPOCGPBAIARAV-JJVMZPRHSA-N (18S)-resolvin E1 Chemical compound CC[C@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-JJVMZPRHSA-N 0.000 claims description 3
- KPRHYAOSTOHNQA-SFHVADPASA-N (18S)-resolvin E2 Chemical compound CC[C@H](O)\C=C\C=C/C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O KPRHYAOSTOHNQA-SFHVADPASA-N 0.000 claims description 3
- CRDZYJSQHCXHEG-XLBFCUQGSA-N (4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/[C@@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-XLBFCUQGSA-N 0.000 claims description 3
- FRJZMMUVPROLHN-PXDZPDTHSA-N (4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid Chemical compound C[C@@H](O)\C=C/C\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O FRJZMMUVPROLHN-PXDZPDTHSA-N 0.000 claims description 3
- FRJZMMUVPROLHN-XEGNPPHTSA-N (4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid Chemical compound C[C@H](O)\C=C/C\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O FRJZMMUVPROLHN-XEGNPPHTSA-N 0.000 claims description 3
- FRJZMMUVPROLHN-KZPAZRNKSA-N (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid Chemical compound C[C@@H](O)\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O FRJZMMUVPROLHN-KZPAZRNKSA-N 0.000 claims description 3
- BOFBVWROGCPAFH-VEYGSZKMSA-N (4Z,9E,11E,13Z,15E,17S,19Z)-7,8-epoxy-17-hydroxydocosahexaenoic acid Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/C=C/C1OC1C\C=C/CCC(O)=O BOFBVWROGCPAFH-VEYGSZKMSA-N 0.000 claims description 3
- IKFAUGXNBOBQDM-FYSWCGKBSA-N (4z,7s,8e,10z,12e,14e,16r,17r,19z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoic acid Chemical compound CC\C=C/C[C@@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)C\C=C/CCC(O)=O IKFAUGXNBOBQDM-FYSWCGKBSA-N 0.000 claims description 3
- IDEHSDHMEMMYIR-DJWFCICMSA-N 11(R)-HEPE Chemical compound CC\C=C/C\C=C/C=C/[C@H](O)C\C=C/C\C=C/CCCC(O)=O IDEHSDHMEMMYIR-DJWFCICMSA-N 0.000 claims description 3
- IDEHSDHMEMMYIR-HODZVVMCSA-N 11S-HEPE Chemical compound CC\C=C/C\C=C/C=C/[C@@H](O)C\C=C/C\C=C/CCCC(O)=O IDEHSDHMEMMYIR-HODZVVMCSA-N 0.000 claims description 3
- MCRJLMXYVFDXLS-UOLHMMFFSA-N 12(S)-HEPE Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-UOLHMMFFSA-N 0.000 claims description 3
- JSFATNQSLKRBCI-UDQWCNDOSA-N 15(R)-HETE Chemical compound CCCCC[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-UDQWCNDOSA-N 0.000 claims description 3
- WLKCSMCLEKGITB-DBVSHIMFSA-N 15(S)-HEPE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-DBVSHIMFSA-N 0.000 claims description 3
- JSFATNQSLKRBCI-VAEKSGALSA-N 15(S)-HETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 claims description 3
- UXVRTOKOJOMENI-SKYGSKSRSA-N 15-epi-lipoxin B4 Chemical compound CCCCC[C@@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-SKYGSKSRSA-N 0.000 claims description 3
- SWTYBBUBEPPYCX-NGHKTGSUSA-N 17(R)-HDoHE Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O SWTYBBUBEPPYCX-NGHKTGSUSA-N 0.000 claims description 3
- LRWYBGFSVUBWMO-OKIFYYRFSA-N 18(S)-HEPE Chemical compound CC[C@H](O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O LRWYBGFSVUBWMO-OKIFYYRFSA-N 0.000 claims description 3
- WYCMUVNNXSREQB-BBJRFLMCSA-N 18S-Resolvin E3 Chemical compound CC[C@H](O)[C@H](O)\C=C\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WYCMUVNNXSREQB-BBJRFLMCSA-N 0.000 claims description 3
- JTGJRDREFMAMJA-MPPNEBGGSA-N 20-Hydroxy-Resolvin E1 Chemical compound OCC[C@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O JTGJRDREFMAMJA-MPPNEBGGSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000036490 Arterial inflammations Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 3
- 229920000896 Ethulose Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 3
- 206010015943 Eye inflammation Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- OIWTWACQMDFHJG-BJEBZIPWSA-N aspirin-triggered resolvin D1 Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-BJEBZIPWSA-N 0.000 claims description 3
- QBTJOLCUKWLTIC-AXRBAIMGSA-N aspirin-triggered resolvin D3 Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCC(O)=O QBTJOLCUKWLTIC-AXRBAIMGSA-N 0.000 claims description 3
- YKPLJNOOLKUEBS-MMOUQCFBSA-N aspirin-triggered resolvin D4 Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCC(O)=O YKPLJNOOLKUEBS-MMOUQCFBSA-N 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 229940106134 krill oil Drugs 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- UXVRTOKOJOMENI-WLPVFMORSA-N lipoxin B4 Chemical compound CCCCC[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-WLPVFMORSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000018360 neuromuscular disease Diseases 0.000 claims description 3
- CRDZYJSQHCXHEG-SFVBTVKNSA-N protectin D1 Chemical compound CC\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-SFVBTVKNSA-N 0.000 claims description 3
- QBTJOLCUKWLTIC-UZAFJXHNSA-N resolvin D3 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCC(O)=O QBTJOLCUKWLTIC-UZAFJXHNSA-N 0.000 claims description 3
- JKPUWSZSJINVLB-OSKNXYPTSA-N resolvin D6 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/C=C/[C@@H](O)CCC(O)=O JKPUWSZSJINVLB-OSKNXYPTSA-N 0.000 claims description 3
- KPRHYAOSTOHNQA-NNQKPOSRSA-N resolvin E2 Chemical compound CC[C@@H](O)\C=C\C=C/C\C=C/C\C=C/C=C/[C@@H](O)CCCC(O)=O KPRHYAOSTOHNQA-NNQKPOSRSA-N 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- IXAQOQZEOGMIQS-SSQFXEBMSA-M lipoxin A4(1-) Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O IXAQOQZEOGMIQS-SSQFXEBMSA-M 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- WLKCSMCLEKGITB-MXTKCVSJSA-N 15(R)-HEPE Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-MXTKCVSJSA-N 0.000 claims 1
- IXAQOQZEOGMIQS-JEWNPAEBSA-N 15-epi-lipoxin A4 Chemical compound CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-JEWNPAEBSA-N 0.000 claims 1
- ZXZLVQGNVOKCAS-UHFFFAOYSA-N 4-(cyclopentylamino)-2-[(2-methoxyphenyl)methylamino]-n-[3-(2-oxopyrrolidin-1-yl)propyl]pyrimidine-5-carboxamide Chemical compound COC1=CC=CC=C1CNC(N=C1NC2CCCC2)=NC=C1C(=O)NCCCN1C(=O)CCC1 ZXZLVQGNVOKCAS-UHFFFAOYSA-N 0.000 claims 1
- OZXAIGIRPOOJTI-VLGMZSPHSA-N 7-hdohe Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C=C\C(O)C\C=C/CCC(O)=O OZXAIGIRPOOJTI-VLGMZSPHSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 119
- 229940090949 docosahexaenoic acid Drugs 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 235000014113 dietary fatty acids Nutrition 0.000 description 23
- 229930195729 fatty acid Natural products 0.000 description 23
- 239000000194 fatty acid Substances 0.000 description 23
- 150000004665 fatty acids Chemical class 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 238000010907 mechanical stirring Methods 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 12
- 230000009102 absorption Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 10
- 235000003599 food sweetener Nutrition 0.000 description 10
- 235000010241 potassium sorbate Nutrition 0.000 description 10
- 239000004302 potassium sorbate Substances 0.000 description 10
- 229940069338 potassium sorbate Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000004376 Sucralose Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000012754 curcumin Nutrition 0.000 description 9
- 239000004148 curcumin Substances 0.000 description 9
- 229940109262 curcumin Drugs 0.000 description 9
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000004626 essential fatty acids Nutrition 0.000 description 9
- 238000009776 industrial production Methods 0.000 description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 9
- 235000010234 sodium benzoate Nutrition 0.000 description 9
- 239000004299 sodium benzoate Substances 0.000 description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 9
- 235000019408 sucralose Nutrition 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 229930003427 Vitamin E Natural products 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 239000000811 xylitol Substances 0.000 description 7
- 235000010447 xylitol Nutrition 0.000 description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 7
- 229960002675 xylitol Drugs 0.000 description 7
- 235000019501 Lemon oil Nutrition 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000010501 lemon oil Substances 0.000 description 6
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 6
- 229940038773 trisodium citrate Drugs 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 244000099147 Ananas comosus Species 0.000 description 5
- 235000007119 Ananas comosus Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 4
- AQZFHYYQYWQFAV-UHFFFAOYSA-N 4-acetyloxy-2,3-dihydroxy-4-oxobutanoic acid Chemical compound CC(=O)OC(=O)C(O)C(O)C(O)=O AQZFHYYQYWQFAV-UHFFFAOYSA-N 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 4
- 235000019477 peppermint oil Nutrition 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 3
- SWTYBBUBEPPYCX-VIIQGJSXSA-N (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O SWTYBBUBEPPYCX-VIIQGJSXSA-N 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 235000004936 Bromus mango Nutrition 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 241001454694 Clupeiformes Species 0.000 description 3
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 102000003820 Lipoxygenases Human genes 0.000 description 3
- 108090000128 Lipoxygenases Proteins 0.000 description 3
- 240000007228 Mangifera indica Species 0.000 description 3
- 235000014826 Mangifera indica Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000009184 Spondias indica Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000019513 anchovy Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000019568 aromas Nutrition 0.000 description 3
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 3
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000008384 inner phase Substances 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- FRJZMMUVPROLHN-PPFGPZQYSA-N (4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid Chemical compound C[C@H](O)\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCC(O)=O FRJZMMUVPROLHN-PPFGPZQYSA-N 0.000 description 2
- WYCMUVNNXSREQB-HVPSRUGQSA-N (5z,8z,11z,13e,15e,17r,18r)-17,18-dihydroxyicosa-5,8,11,13,15-pentaenoic acid Chemical compound CC[C@@H](O)[C@H](O)\C=C\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WYCMUVNNXSREQB-HVPSRUGQSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- IXAQOQZEOGMIQS-JEWNPAEBSA-M CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O Chemical compound CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O IXAQOQZEOGMIQS-JEWNPAEBSA-M 0.000 description 2
- 108010055167 CD59 Antigens Proteins 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 235000016401 Camelina Nutrition 0.000 description 2
- 244000197813 Camelina sativa Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229920002807 Thiomer Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020235 chia seed Nutrition 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- YKPLJNOOLKUEBS-RIYRYSNMSA-N resolvin D4 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCC(O)=O YKPLJNOOLKUEBS-RIYRYSNMSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000013570 smoothie Nutrition 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000003977 synaptic function Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IBBMPLHGPUWBAM-UHFFFAOYSA-N 2-acetyl-2,3-dihydroxybutanedioic acid Chemical compound CC(=O)C(O)(C(O)=O)C(O)C(O)=O IBBMPLHGPUWBAM-UHFFFAOYSA-N 0.000 description 1
- UBXSGWANZATOLV-UHFFFAOYSA-N 3,4-dihydroxy-3-(hydroxymethyl)butan-2-one Chemical compound CC(=O)C(O)(CO)CO UBXSGWANZATOLV-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001125048 Sardina Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- ORYOIBJWFDNIPD-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O ORYOIBJWFDNIPD-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DQRSJOZDBPWTCH-UHFFFAOYSA-N docosa-1,3,5-triene Chemical class CCCCCCCCCCCCCCCCC=CC=CC=C DQRSJOZDBPWTCH-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 125000002742 lipoxin A4 group Chemical group 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000013663 muscle adaptation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000021301 omega-3 deficiency Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000005672 tetraenes Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/192—Monoglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5086—Xanthan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
- A23V2250/51082—Carboxymethyl cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
- A23V2250/51084—Crystalline, microcrystalline cellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
1)少なくとも2つのセルロース誘導体を含んでいる水相を調製すること;
2)上記水相の激しい撹拌によって、セルロース誘導体の混合物を活性化させること;
3)少なくとも1つの親水性乳化剤を上記水相に加えること;
4)オメガ−3脂肪酸を含んでいる油を含んでいる油相を調製すること;
5)上記水相および油相を混合すること、続く均質化;
を含んでいる。
1)オメガ−3脂肪酸を含んでいる、1.0〜40重量%の油;
2)0.1〜5.0重量%のセルロース誘導体;
3)0.1〜10重量%の親水性乳化剤;
(ここで、すべての重量%は、上記エマルションの総重量に基づく)
を含んでいることを特徴とする。
1)オメガ−3脂肪酸を含んでいる、1.0〜30重量%の油;
2)0.4〜1.5重量%のセルロース誘導体;
3)0.2〜3.0重量%の親水性乳化剤;
(ここで、すべての重量%は、上記エマルションの総重量に基づく)
を含んでいることを特徴とする。
1)少なくとも2つのセルロース誘導体を含んでいる水相を調製すること;
2)上記水相の激しい撹拌によって複数のセルロース誘導体の混合物を、当該複数の誘導体の結合を容易にし、かつそれによって秩序だった微小構造を形成するために、活性化すること;
3)少なくとも1つの親水性乳化剤を上記水相に加えること;
4)オメガ−3脂肪酸を含んでいる油を含んでいる油相を調製すること;ならびに
5)上記水相および油相を混合すること、続く均質化;
を含んでいる。
水中のエチルエステル(EE)の形態における95kgのオメガ−3脂肪酸エマルション(EMOX−1)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表2は、エマルションの組成を示している。
水中のトリグリセリドの形態における95kgのオメガ−3脂肪酸エマルション(EMOX−2)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表4は、エマルションの組成を示している。
水中のモノグリセリド(MG)の形態における95kgのオメガ−3脂肪酸エマルション(EMOX−3)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表6は、エマルションの組成を示している。
トリグリセリドの形態でオメガ−3脂肪酸を水中に含んでいる、200gのオイルエマルション(30/20TG)(EMOX−4)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表8は、エマルションの組成を示している。
水中のモノグリセリド(モノアセチルグリセリド)の形態における100gのオメガ−3脂肪酸エマルション(EMOX−5)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表10は、エマルションの組成を示している。
水中の25kgのオメガ−3脂肪酸エマルションおよび5%SPM(EMOX−6)の工業生産を実施するために、2相(続いて混合され、乳化される水相および油相)を、室温で調製した。表12は、エマルションの組成を示している。
ArdalanMR, Rafieian-Kopaei M. Antioxidant supplementation in hypertension. J Renal InjPrev. 3:39-40. (2014).
BaradaranA. Lipoprotein (a), type 2 diabetes and nephropathy; the mystery continues. JNephropathol.1:126-9. (2012).
BirchD G, Birch E E, Hoffman D R, Uauy R D. Retinal development invery-low-birth-weight infants fed diets differing in omega-3 fatty acids.Invest. Ophthalmol. Vis. Sci. 33, 2365-2376. (1992a).
BirchEE, Birch DG, Hoffman DR et al. Dietary essential fatty acid supply and visualacuity development. Invest Ophthalmol Vis Sci. 33:3242-3253. (1992b).
BirchEE, Hoffman D, Uauy R et al. Visual acuity and the essentiality ofdocosahexaenoic acid and arachidonic acid in the diet of term infants.Pediatric Research. 44:201-209. (1998).
BourreJ, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G et al.. The effects ofdietary a-linolenic acid on the composition of nerve membranes, enzymaticactivity, amplitude of electrophysiological parameters, resistance to poisonsand performance of learning tasks in rats. J Nutr. 119:1880-90. (1989).
CaoD, Kevala K, Kim J et al. Docosahexaenoic acid promotes hippocampal neuronaldevelopment and synaptic function. J Neurochem.111:510-521. (2009).
CarlsonS. E., Werkman S. H., Rhodes P. G., Tolley E. A. Visual-acuity development inhealthy preterm infants: effect of marine-oil supplementation. Am. J. Clin.Nutr. 58, 35-42. (1993).
CheathamCL, Colombo J, Carlson SE. N-3 fatty acids and cognitive and visual acuitydevelopment: Methodological and conceptual considerations. Am J ClinNutr.83:1458S-1466S. (2006).
Cruz-HernandezC et al., Nutrients, 4, 1781-1793, “Benefits of Structured and FreeMonoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipidmalabsorption” (2012).
Dalli, J,Colas R.A. and Serhan C.N. Novel n-3 Immunoresolvents: Structures and Actions.Nature Scientific Reports 3, Article number: 1940. (2013).
DyallSC. Long-chain omega-3 fatty acids and the brain: a review of the independentand shared effects of EPA, DPA and DHA Frontiers in Aging Neuroscience. 1April, Volume 7, Article 52. (2015).
DurandG, Antoine J M, Couet C. Blood lipid concentrations of docosahexaenoic andarachidonic acids at birth determine their relative postnatal changes in terminfants fed breast milk and formula. Am J Clin Nutr.70:292-298. (1999).
GaraiovaI, Guschina IA, Plummer SF, Tang J, Wang D, Plummer NT. A randomized cross-overtrial in healthy adults indicating improved absorption of omega-3 fatty acidsby pre-emulsification. Nutrition Journal. 6:4.(2007).
GuistoNM, Salvador GA, Castagnet PI. PAsquare SJ, Ilincheta de Bschero MG.Age-associated changes in central nervous system glycerophospholipids compositionand metabolism. Neurochem Res.27:1513-23. (2002).
HibbelnJR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al. Maternal seafoodconsumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPACstudy): an observational cohort study. Lancet. 369:578. (2007).
HongS, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and17S-resolvins generated from docosahexaenoic acid in murine brain, human blood,and glial cells. Autacoids in anti-inflammation. J Biol Chem. Apr 25;278(17):14677-87.Epub 2003 Feb 17. (2003).
IkedaI. Digestion and absorption of structured lipids. In: Chrisyophe AG, DeVrieseS, editors. Fat Digestion and Absorption. AOCS Press; Champaign, IL. pp. 235-243.(2000).
InnisSM. Essential fatty acid metabolism during early development. In: Biology ofMetabolism in Growing Animals. Burrin DG ed. Pub. Elsevier Science, B.V.Amsterdam. Part III, pp. 235-74, (2005).
LevyBD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switchingduring acute inflammation: signals in resolution. Nat Immunol. Jul;2(7):612-9.(2001).
Lewis EJH,. Radonic PW, Thomas M. S. Wolever TMS and Wells GD. 21 days ofmammalian omega-3 fatty acid supplementation improves aspects of neuromuscularfunction and performance in male athletes compared to olive oil placebo.Journal of the International Society of Sports Nutrition. 12:28. (2015).
LindmarkL, Clough P.A 5-month open study with long-chain polyunsaturated fatty acids indyslexia. J Med Food.10:662-666. (2007).
MazereeuwG, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of ω-3 fatty acids oncognitive performance: a meta-analysis. Neurobiol Aging. Jul;33(7):1482.e17-29.doi: 10.1016/j.neurobiolaging.2011.12.014. Epub 2012 Feb 3. (2012).
MirnikjooB, Brown SE, Kim HF et al. Protein kinase inhibition by ω-3 fatty acids. J BiolChem. 276(14):10888-10896. (2001).
MorinC, Fortin S, Cantin AM, Sirois M, Sirois C, Rizcallah E, Rousseau E.Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lungadenocarcinoma. Recent Pat anticancer Drug Discov. Sep 8,(3):319-34. (2013).
OkenE, Wright RO, Kleinman KP, Bellinger D, Amarasiriwardena CJ, Hu H, et al.Maternal fish consumption, hair mercury, and infant cognition in a U.S. Cohort.Environ Health Perspect.113:1376-80. (2005).
PhilippoussisF, Przybytkowski E, Fortin S, Arguin C , Pande SV, Steff A-M and Hugo P.Derivatives of monoglycerides as apoptotic agents in T-cellsCell Death Differ.8:1103-12. (2001).
Rahimi-MadisehM, Heidarian E, Rafieian-kopaei M. Biochemical components of Berberis lyciumfruit and its effects on lipid profile in diabetic rats. J HerbMedPharmacol.3:15-9. (2014).
RaatzSK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption ofomega-3 fatty acids from emulsified compared with encapsulated fish oil. J AmDiet Assoc. June; 109(6): 1076-1081. (2009).
SerhanCN, Hamberg M and Samuelsson B. Lipoxins: Novel series of biologically activecompounds formed from arachidonic acid in human leukocytes (lipoxygenase interactionproducts/conjugated tetraenes/human neutrophils), Proc. Nati. Acad. Sci. USA,Vol. 81, pp. 5335-5339, September (1984).
SerhanCN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional setsof lipid-derived mediators with antiinflammatory actions generated from Omega-3fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs andtranscellular processing. J Exp Med. Oct 16; 192(8):1197-204. (2000).
SerhanCN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL.Resolvins: a family of bioactive products of Omega-3 fatty acid transformationcircuits initiated by aspirin treatment that counter proinflammation signals. JExp Med. Oct 21;196(8):1025-37. (2002).
SmithersL. G., Gibson R. A., McPhee A., Makrides M. Higher dose of docosahexaenoic acidin the neonatal period improves visual acuity of preterm infants: results of arandomized controlled trial. Am. J. Clin. Nutr. 88, 1049-1056. (2008).
TavafiM. Diabetic nephropathy and antioxidants. J Nephropathol. 2:20-7. (2013).
UauyR, Dangour AD. Nutrition in brain development and aging: role of essentialfatty acids. Nutr Rev. 64:S24-33. (2006).
UauyR, Mena P, Rojas C. Essential fatty acids in early life: structural andfunctional role. Proc Nutr Soc. 59:3-15. (2000).
YehudaS, Rabinovitz S, Mostofsky D I. Essential fatty acids are mediators of brainbiochemistry and cognitive functions. J Neurosci Res. 56:565-570. (1999).
CA2455226 C、発明の名称「Compositions comprising an o/w emulsioncontaining conjugated linoleic acid」
CN103432588 A、発明の名称「Copolymer for preparation ofprobiotic microcapsule and preparation method thereof」
CN104274836 A、発明の名称「Making method for improvement of drugpalatability」
CN100486567 C、発明の名称「Curcumin emulsion and its preparationprocess」
EP1116515 A2、発明の名称「Encapsulated liquid」
EP0868918 B1、発明の名称「Vaccines comprising oil/water emulsionwith tocopherol and squalene」
EP2344140 B1、発明の名称「a method for the production ofbioadhesive compact matrices」
EP2595611 A2、発明の名称「Multiple unit tablet composition」
PCT/CA2008/000530、発明の名称「Compositions comprising polyunsaturated fatty acid monoglycerides orderivatives thereof and uses thereof」
PCT/CA2008/000301、発明の名称「Polyunsaturated fatty acid monoglycerides, derivatives, and usesthereof」
UA 99889C2、発明の名称「Composition Ingredient For MucoadhesivePolymer」
US20060029622 A1、発明の名称「Water in oil emulsion comprisingsterolesters」
US20090142324 A1、発明の名称「Oil-in-water type emulsioncontaining coenzyme q10 and process for producing the same」
US20090208472 A1、発明の名称「Oil-in-water emulsion compositioncontaining licorice-derived polyphenol」
US20140170247 A1、発明の名称「Emulsion of Carotenoids and OcularAntioxidants」
US201502384 A1、発明の名称「Disintegrating particle compositioncontaining acid-type carboxymethyl cellulose and crystalline cellulose, andorally disintegrating tablet containing said」
US2463738 A、発明の名称「Stable emulsions of oil and glycerine」
US3089823 A、発明の名称「Aqueous vitamin an oil emulsion」
US5773073 A、発明の名称「Water-in-oil emulsion containing a polyglycerolfatty acid ester having erucic acid as the main fatty acid component」
US6007856 A、発明の名称「Oil-in-water dispersions of β-caroteneand other carotenoids stable against oxidation prepared from water-dispersiblebeadlets having high concentrations of carotenoid」
US8512687 B2、発明の名称「Oil in water emulsion comprisingNSAIDs and quaternary ammonium halides」
WO 99/63841、発明の名称「Compositions comprising phytosterol and/or phytostanol havingenhanced solubility and dispersability」
WO2003004015 A1、発明の名称「Oil-in-water emulsions comprising abenzodiazepine drug」
WO2011049629 A2、発明の名称「Methods of making and usingcompositions comprising flavonoids」
WO2014051116 A1、発明の名称「Lycopene-containing oil-in-wateremulsion composition and production method therefor」
WO2015102189 A1、発明の名称「Enteric coating composition,enteric coating film and food preparation」
WO2015104440 A1、発明の名称「Edible coating for preservingpieces of fruit, production method and application thereof」
Claims (27)
- 水中油エマルションであって、
上記油がオメガ−3脂肪酸を含んでおり、上記エマルションがまた少なくとも2つのセルロース誘導体および少なくとも1つの親水性乳化剤を含んでいる、エマルション。 - 上記少なくとも2つのセルロース誘導体は、上記油が配置されている三次元ネットワークを形成する水素結合によって結合されている、請求項1に記載のエマルション。
- 上記セルロース誘導体が、微結晶セルロース、カルボキシメチルセルロースナトリウム、エチルヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース(HPMC)、ヒドロキシエチルメチルセルロース、ヒドロキシプロピルセルロース(HPC)、ヒドロキシエチルセルロース、エチルメチルセルロース、エチルセルロース、メチルセルロース、キサンタンガム、グアールガムおよび/またはアラビアゴムから選択されることを特徴とする請求項1または2に記載のエマルション。
- 上記セルロース誘導体が、微結晶セルロース、カルボキシメチルセルロースおよび/またはキサンタンガムから選択される、請求項3に記載のエマルション。
- セルロース誘導体の総含有量が、上記エマルションの総重量に対して5重量%未満であることを特徴とする請求項1〜4のいずれか1項に記載のエマルション。
- 1)オメガ−3脂肪酸を含んでいる、1.0〜40重量%の油;
2)0.1〜5.0重量%のセルロース誘導体;および
3)0.1〜10重量%の親水性乳化剤;
(ここで、すべての重量%は、上記エマルションの総重量に基づく)
を含んでいることを特徴とする請求項1〜5のいずれか1項に記載のエマルション。 - 1)オメガ−3脂肪酸を含んでいる、1.0〜30重量%の油;
2)0.4〜1.5重量%のセルロース誘導体;および
3)0.2〜3.0重量%の親水性乳化剤;
(ここで、すべての重量%は、上記エマルションの総重量に基づく)
を含んでいることを特徴とする請求項1〜6のいずれか1項に記載のエマルション。 - 上記オメガ−3脂肪酸を含んでいる上記油が、魚油、オキアミの油、植物油、微生物の油、および/またはこれらの組み合わせに由来する、請求項1〜7のいずれか1項に記載のエマルション。
- 上記オメガ−3脂肪酸を含んでいる上記油が、魚油に由来する、請求項8に記載のエマルション。
- 上記エマルションの総重量に対して、少なくとも1重量%のエイコサペンタエン酸(EPA)および/またはドコサヘキサエン酸(DHA)を含んでいる、請求項8または9に記載のエマルション。
- 上記エマルションの総重量に対して、少なくとも1重量%のドコサペンタエン酸n−3(DPA n−3)を含んでいる、請求項8または9に記載のエマルション。
- 上記エマルションの総重量に対して、少なくとも5重量%のエイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)および/またはドコサペンタエン酸n−3(DPA n−3)を含んでいる、請求項8または9に記載のエマルション。
- 上記オメガ−3脂肪酸が、遊離脂肪酸、エステル、リン脂質、モノグリセリド、ジグリセリド、トリグリセリド、および/またはこれらの組み合わせの形態である、請求項1〜12のいずれか1項に記載のエマルション。
- 上記オメガ−3脂肪酸が、モノグリセリドの形態である、請求項13に記載のエマルション。
- 上記オメガ−3脂肪酸が、C1〜C8アルキルエステルの形態である、請求項13に記載のエマルション。
- 上記油がまた炎症消退性脂質メディエータ(SPM)を含んでいる、請求項1〜15のいずれか1項に記載のエマルション。
- 上記炎症消退性脂質メディエータ(SPM)が、リポキシンA4、15−エピリポキシンA4、リポキシンB4、15−エピリポキシンB4、RvE1、18S−RvE1、20−ヒドロキシ−RvE1、RvE2、18S−RvE2、18S−RvE3、18R−RvE3、MaR1、7S−MaR1、13R,14S−MaR2、14S−ヒドロペルオキシ−DHA,PDX、14S,21R−ジHDHA、14R,21S−ジHDHA、14R,21R−ジHDHA、14S,21S−ジHDHA、16,17−ジHDHA、16,17−エポキシ−DHA、7,8−エポキシ−17S−HDHA、PD1、10S,17S−HDHA、16,17−ジHDHA、16,17−エポキシ−DHA、RvD1、RvD2、RvD3、RvD4、RvD5、RvD6、AT−RvD1、AT−RvD2、AT−RvD3、AT−RvD4、10S,17S−HDPAn−6、17−HDPA n−6、7,14−HDPA n−6、10S,17S−HDPA n−6、7,17−HDPA n−6、15S−HETE、15R−HETE、5S−HEPE、5R−HEPE、11S−HEPE、11R−HEPE、12S−HEPE、12R−HEPE、15S−HEPE、15R−HEPE、18S−HEPE、18R−HEPE、4S−HDHA、7S−HDHA、10S−HDHA、11S−HDHA、14S−HDHA、14R−HDHA、17S−HDHA、17R−HDHA、20S−HDHA、17S−HDPAn−6、14S−HDPA n−6、10S−HDPA n−6、17S−HDPA n−3、14S−HDPA n−3、10S−HDPA n−6、17−HpDPA n−3、17−ヒドロペルオキシ−DPAn−3、RvD1 n−3DPA、RvD2 n−3DPA、RvD5 n−3DPA、PD1 n−3DPA、PD2 n−3DPA、14−HpDHA、MaR1 n−3DPA、MaR2n−3DPA、およびMaR3 n−3DPA、ならびにそれらの混合物から選択される、請求項16に記載のエマルション。
- 上記炎症消退性脂質メディエータ(SPM)が、8R/S−HEPE、17R/S−HDHA、5S−HEPE、15R/S−HEPE、4R/S−HDHA、7R/S−HDHA、10R/S−HDHA、14R/S−HDHAおよびRvE1、ならびにそれらの混合物から選択される、請求項16または17に記載のエマルション。
- 0.0005重量%〜1重量%の、17S/R−HDHAおよび18S/R−HEPEの混合物を含んでいる(ここで、すべての重量%は、上記エマルションの総重量に基づく)、請求項18に記載のエマルション。
- 1)少なくとも2つのセルロース誘導体を含んでいる水性相を調製するステップ;
2)上記水性相の激しい撹拌によってセルロース誘導体の混合物を活性化するステップ;
3)少なくとも1つの乳化剤を上記水性相に加えるステップ;
4)上記オメガ−3脂肪酸を含んでいる上記油を含んでいる油相を調製するステップ;ならびに
5)上記水性相および油相を混合し、続いて均質化するステップ;
を含んでいる、請求項1〜19のいずれか1項に記載のエマルションを調製するための、方法。 - 請求項20にしたがって入手可能な水中油エマルション。
- 栄養補助食品、栄養補助剤製品、医療食品、薬学的組成物、医薬品としての、スポーツ栄養法、経腸栄養法および/または小児栄養法における、請求項1〜19および21のいずれか1項に規定されている通りのエマルションの、使用。
- 経腸栄養法における、請求項1〜19および21のいずれか1項に規定されている通りのエマルションの、使用。
- 栄養補助食品、栄養補助剤製品、医療食品および/または薬学的組成物としての、請求項1〜19および21のいずれか1項に規定されている通りのエマルションの、使用。
- 医療食品としての、請求項1〜19および21のいずれか1項に記載のエマルションの、使用。
- 炎症性コンポネントを示す疾患または障害を処置するための、投与の経腸経路用医薬品を製造するための、請求項1〜19および21のいずれか1項に記載のエマルションの、使用。
- 炎症性コンポネントを示している上記疾患または障害が、クローン病、IBD、脂肪肝、創傷治癒、動脈の炎症、関節炎、乾癬、蕁麻疹、血管炎、喘息、眼の炎症、肺の炎症、皮膚炎、心疾患、AIDS、アルツハイマー病、アテローム性動脈硬化症、がん、2型糖尿病、高血圧、神経筋の障害、肥満、感染症、白血病、リンパ腫、代謝症候群、肥満、心臓発作、リウマチ、移植、歯周病、脳外傷、外傷、嚢胞性線維症および筋疾患から選択される、請求項26に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022020799A JP2022065087A (ja) | 2015-10-01 | 2022-02-14 | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201531406 | 2015-10-01 | ||
ES201531406A ES2607715B1 (es) | 2015-10-01 | 2015-10-01 | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa |
PCT/IB2016/055902 WO2017056075A1 (es) | 2015-10-01 | 2016-10-03 | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022020799A Division JP2022065087A (ja) | 2015-10-01 | 2022-02-14 | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018531251A true JP2018531251A (ja) | 2018-10-25 |
JP2018531251A6 JP2018531251A6 (ja) | 2018-12-13 |
JP7360793B2 JP7360793B2 (ja) | 2023-10-13 |
Family
ID=57233790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018517314A Active JP7360793B2 (ja) | 2015-10-01 | 2016-10-03 | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
JP2022020799A Pending JP2022065087A (ja) | 2015-10-01 | 2022-02-14 | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022020799A Pending JP2022065087A (ja) | 2015-10-01 | 2022-02-14 | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10856564B2 (ja) |
EP (1) | EP3357351B1 (ja) |
JP (2) | JP7360793B2 (ja) |
CN (1) | CN108366600B (ja) |
AU (1) | AU2016333026B2 (ja) |
CA (1) | CA3000103C (ja) |
ES (2) | ES2607715B1 (ja) |
WO (1) | WO2017056075A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022065087A (ja) * | 2015-10-01 | 2022-04-26 | ソルテックス エヌエー,エルシーシー | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05168415A (ja) * | 1982-11-04 | 1993-07-02 | Rich Prod Corp | 乳化食品への添加に適した安定剤組成物 |
JP2001503743A (ja) * | 1996-10-11 | 2001-03-21 | スコティア ホールディングズ ピー エル シー | エイコサペンタエン酸および/またはステアリドン酸を含む治療用薬剤 |
JP2005529728A (ja) * | 2002-06-18 | 2005-10-06 | マーテック・バイオサイエンシーズ・コーポレーション | 水溶液中の油の安定エマルジョンおよびその製造方法 |
JP2007517859A (ja) * | 2004-01-06 | 2007-07-05 | フリードマン、ドロン | 不溶性生物活性物質の経口投与用無水組成物 |
JP2009500151A (ja) * | 2005-07-04 | 2009-01-08 | ビーエーエスエフ ソシエタス・ヨーロピア | 乳化剤系、エマルジョンおよびその使用 |
JP2009505809A (ja) * | 2005-07-04 | 2009-02-12 | ビーエーエスエフ ソシエタス・ヨーロピア | 乳化剤系、そのエマルジョンおよびその使用 |
JP2009118821A (ja) * | 2007-11-19 | 2009-06-04 | Taiyo Kagaku Co Ltd | 乳含有飲料用安定化組成物 |
JP2013526289A (ja) * | 2010-05-17 | 2013-06-24 | アボット・ラボラトリーズ | 封入された油を含有する栄養エマルジョンの作製方法 |
JP2013527795A (ja) * | 2010-04-09 | 2013-07-04 | ディーエスエム アイピー アセッツ ビー.ブイ. | 多価不飽和脂肪酸を含有する油を含有する熱安定性水中油エマルジョン |
JP2013544102A (ja) * | 2010-11-30 | 2013-12-12 | ネステク ソシエテ アノニム | 液体クリーマー及びその製造方法 |
JP2015522535A (ja) * | 2012-05-10 | 2015-08-06 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2463738A (en) | 1947-08-13 | 1949-03-08 | Wyeth Corp | Stable emulsions of oil and glycerine |
US3089823A (en) | 1961-09-05 | 1963-05-14 | Eastman Kodak Co | Aqueous vitamin a oil emulsion |
JP2995855B2 (ja) | 1989-11-28 | 1999-12-27 | 三菱化学株式会社 | 油中水型乳化物および保水性改善剤 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6007856A (en) | 1997-08-08 | 1999-12-28 | The Procter & Gamble Company | Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid |
NZ508645A (en) | 1998-06-05 | 2003-10-31 | Forbes Medi Tech Inc | Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability and the use of these compositions to lower serum cholesterol |
EP1116515A3 (en) | 2000-01-11 | 2002-08-21 | Givaudan SA | Encapsulated liquid |
GB0012597D0 (en) * | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
GB0105622D0 (en) | 2001-03-07 | 2001-04-25 | Natural Asa | Compositions |
GB0116107D0 (en) | 2001-06-30 | 2001-08-22 | West Pharm Serv Drug Res Ltd | Pharmaceutical composition |
HUE041471T2 (hu) * | 2002-08-12 | 2019-05-28 | Brigham & Womens Hospital | Rezolvinok: Biotemplátok terápiás beavatkozásokhoz |
ATE354973T1 (de) | 2002-10-31 | 2006-03-15 | Unilever Nv | Sterolester und folsäure enthaltende wasser-in-öl emulsion |
DE602004023823D1 (de) | 2003-03-11 | 2009-12-10 | Kaneka Corp | Öl-in-wasser-emulsion, die coenzym q10 enthält, und verfahren zu ihrer herstellung |
US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
CN100486567C (zh) | 2004-08-12 | 2009-05-13 | 山东绿叶天然药物研究开发有限公司 | 姜黄素乳剂及其制备方法 |
US9452150B2 (en) * | 2004-08-18 | 2016-09-27 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
TW200806306A (en) | 2006-02-24 | 2008-02-01 | Kaneka Corp | Oil-in-water emulsion composition containing licorice-derived polyphenol |
CA2655985A1 (en) * | 2006-06-23 | 2007-12-27 | The Procter & Gamble Company | Concentrated omega-3 fatty acids and mixtures containing them |
WO2008145183A1 (en) | 2007-05-30 | 2008-12-04 | Nestec S.A. | Oil-in-water emulsion and its use for the delayed release of active elements |
US8512687B2 (en) | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
US8399039B2 (en) * | 2007-11-29 | 2013-03-19 | Nestec S.A. | Shelf stable liquid whitener and process of making thereof |
US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
EP2163240A1 (en) | 2008-09-12 | 2010-03-17 | Universita' Degli Studi Di Genova | A method for the production of bioadhesive compact matrices |
JP5168415B2 (ja) | 2009-09-16 | 2013-03-21 | コニカミノルタオプティクス株式会社 | 生体情報測定システムならびに生体情報測定装置の使用方法および通信方法 |
BR112012011336A2 (pt) | 2009-10-22 | 2018-10-16 | Api Genesis Llc | Composições compreendendo flavonoides, seu método de preparação, adesivo para aplicação de flavonoide, métodos de produção de flavonoide hidratado,métodos de preparação de formulação tópica, e uso de flavonoide |
WO2011060084A1 (en) * | 2009-11-10 | 2011-05-19 | MyCell Holdings Limited | Stabilized formulations of fatty acids |
JP5816271B2 (ja) * | 2010-05-17 | 2015-11-18 | アボット・ラボラトリーズAbbott Laboratories | 封入された油を含む栄養エマルジョン |
WO2012010944A2 (en) | 2010-07-22 | 2012-01-26 | Lupin Limited | Multiple unit tablet composition |
US20120251685A1 (en) * | 2011-04-04 | 2012-10-04 | Martek Biosciences Corporation | Oil-in-Water Emulsions Comprising a Polyunsaturated Fatty Acid and Methods of Making the Same |
US20130004617A1 (en) * | 2011-07-01 | 2013-01-03 | Pepsico, Inc. | Coacervate complexes, methods and food products |
UA99889C2 (ru) | 2011-12-13 | 2012-10-10 | Физико-Химический Институт Им. А.В. Богатского Национальной Академии Наук Украины | Композиция ингредиентов для мукоадгезивных полимерных пленок |
US20140170247A1 (en) | 2012-09-14 | 2014-06-19 | Guardion Health Sciences, Llc | Emulsion of Carotenoids and Ocular Antioxidants |
IN2015DN02907A (ja) | 2012-09-20 | 2015-09-11 | Daicel Corp | |
EP2902101A4 (en) | 2012-09-28 | 2016-03-02 | Fujifilm Corp | WATER OIL EMULSION COMPOSITION CONTAINING LYCOPENE AND METHOD FOR PRODUCING THE SAME |
US9489051B2 (en) | 2013-07-01 | 2016-11-08 | Blackberry Limited | Display navigation using touch-less gestures |
CN104274836A (zh) | 2013-07-07 | 2015-01-14 | 青岛康地恩药业股份有限公司 | 一种改善药物适口性的制作方法 |
CN103432588A (zh) | 2013-08-29 | 2013-12-11 | 安徽大学 | 一种可用于制备益生菌微胶囊的共聚物及其制备方法 |
WO2015079414A1 (en) * | 2013-11-28 | 2015-06-04 | University Of Saskatchewan | Crystalline cellulose gel-based cryptands, surface active agents, emulsions and vesicles |
KR20150079282A (ko) | 2013-12-31 | 2015-07-08 | 삼성정밀화학 주식회사 | 장용성 코팅 조성물, 장용성 코팅막 및 식품 제제 |
ES2540403B1 (es) | 2014-01-07 | 2016-05-12 | Production And Innovation On Edible Coatings, S.L. | Recubrimiento comestible para la conservación de trozos de fruta, su proceso de fabricación y de aplicación |
CN104366508A (zh) | 2014-11-13 | 2015-02-25 | 天津禹王生物医药科技有限公司 | 一种叶黄素酯或叶黄素乳液及制备方法 |
ES2607715B1 (es) * | 2015-10-01 | 2018-01-17 | Solutex Na, Lcc | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa |
-
2015
- 2015-10-01 ES ES201531406A patent/ES2607715B1/es not_active Expired - Fee Related
-
2016
- 2016-10-03 WO PCT/IB2016/055902 patent/WO2017056075A1/es active Application Filing
- 2016-10-03 CN CN201680057948.8A patent/CN108366600B/zh active Active
- 2016-10-03 ES ES16791090T patent/ES2831350T3/es active Active
- 2016-10-03 EP EP16791090.0A patent/EP3357351B1/en active Active
- 2016-10-03 US US15/763,763 patent/US10856564B2/en active Active
- 2016-10-03 CA CA3000103A patent/CA3000103C/en active Active
- 2016-10-03 JP JP2018517314A patent/JP7360793B2/ja active Active
- 2016-10-03 AU AU2016333026A patent/AU2016333026B2/en active Active
-
2022
- 2022-02-14 JP JP2022020799A patent/JP2022065087A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05168415A (ja) * | 1982-11-04 | 1993-07-02 | Rich Prod Corp | 乳化食品への添加に適した安定剤組成物 |
JP2001503743A (ja) * | 1996-10-11 | 2001-03-21 | スコティア ホールディングズ ピー エル シー | エイコサペンタエン酸および/またはステアリドン酸を含む治療用薬剤 |
JP2005529728A (ja) * | 2002-06-18 | 2005-10-06 | マーテック・バイオサイエンシーズ・コーポレーション | 水溶液中の油の安定エマルジョンおよびその製造方法 |
JP2007517859A (ja) * | 2004-01-06 | 2007-07-05 | フリードマン、ドロン | 不溶性生物活性物質の経口投与用無水組成物 |
JP2009500151A (ja) * | 2005-07-04 | 2009-01-08 | ビーエーエスエフ ソシエタス・ヨーロピア | 乳化剤系、エマルジョンおよびその使用 |
JP2009505809A (ja) * | 2005-07-04 | 2009-02-12 | ビーエーエスエフ ソシエタス・ヨーロピア | 乳化剤系、そのエマルジョンおよびその使用 |
JP2009118821A (ja) * | 2007-11-19 | 2009-06-04 | Taiyo Kagaku Co Ltd | 乳含有飲料用安定化組成物 |
JP2013527795A (ja) * | 2010-04-09 | 2013-07-04 | ディーエスエム アイピー アセッツ ビー.ブイ. | 多価不飽和脂肪酸を含有する油を含有する熱安定性水中油エマルジョン |
JP2013526289A (ja) * | 2010-05-17 | 2013-06-24 | アボット・ラボラトリーズ | 封入された油を含有する栄養エマルジョンの作製方法 |
JP2013544102A (ja) * | 2010-11-30 | 2013-12-12 | ネステク ソシエテ アノニム | 液体クリーマー及びその製造方法 |
JP2015522535A (ja) * | 2012-05-10 | 2015-08-06 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022065087A (ja) * | 2015-10-01 | 2022-04-26 | ソルテックス エヌエー,エルシーシー | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 |
Also Published As
Publication number | Publication date |
---|---|
US20180271131A1 (en) | 2018-09-27 |
ES2607715B1 (es) | 2018-01-17 |
CA3000103C (en) | 2023-05-02 |
ES2831350T3 (es) | 2021-06-08 |
WO2017056075A1 (es) | 2017-04-06 |
CA3000103A1 (en) | 2017-04-06 |
CN108366600A (zh) | 2018-08-03 |
EP3357351B1 (en) | 2020-08-12 |
ES2607715A1 (es) | 2017-04-03 |
EP3357351A1 (en) | 2018-08-08 |
AU2016333026A2 (en) | 2018-05-10 |
JP7360793B2 (ja) | 2023-10-13 |
AU2016333026A1 (en) | 2018-04-19 |
AU2016333026B2 (en) | 2020-08-27 |
CN108366600B (zh) | 2022-04-29 |
US10856564B2 (en) | 2020-12-08 |
JP2022065087A (ja) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2611808C2 (ru) | Липидная смесь для детского питания | |
RU2276975C2 (ru) | Терапевтические комбинации жирных кислот | |
TWI358292B (en) | Composition with effects of decline prevention, im | |
JP5546087B2 (ja) | 皮膚疾患経口治療または予防剤 | |
DK2814470T3 (en) | Methods, compositions and devices for meeting dietary fatty acid requirements | |
BRPI0910184B1 (pt) | Preparação compreendendo uma mistura derivada de não mamíferos de conjugados de glicerofosfolipídio de soro, uso de uma preparação, e composição nutricional, farmacêutica ou nutracêutica ou alimento funcional | |
KR20030031501A (ko) | 비타민 k 및 필수 지방산 | |
JP2003048831A (ja) | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
US20090099261A1 (en) | Omega-3 mixtures | |
CN115666548A (zh) | 富含lpc-dha和lpc-epa的磷虾油组合物 | |
JP2022065087A (ja) | セルロース誘導体の等軸結晶ネットワークによる、オメガ-3を有しているエマルションの、調製方法および安定化方法 | |
JP2018531251A6 (ja) | セルロース誘導体の等軸結晶ネットワークによる、オメガ−3を有しているエマルションの、調製方法および安定化方法 | |
EP2432328A1 (en) | Fat blends and uses thereof | |
JP6291058B2 (ja) | セリングリセロリン脂質調製物及び発作の治療方法 | |
US20070225370A1 (en) | Nutritional Compositions and Methods | |
EP2273895A1 (fr) | Compositions comprenant de l'acide myristique, des acides gras comprenant un diene conjugue n-5cis, n-7trans ou un triene conjugue n-5cis, n-7trans, n-9cis | |
Bhat | Functional lipids as nutraceuticals: A review | |
JP2012082226A (ja) | 皮膚疾患経口治療または予防剤 | |
US20170042947A1 (en) | Unsaturated fatty acid absorption accelerator | |
Ultra | Product Comparison Chart | |
JP2009084244A (ja) | 皮膚バリア機能改善剤等 | |
JP2008247792A (ja) | 便通改善剤 | |
JP2014205710A (ja) | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 | |
JP2006121957A (ja) | ドコサヘキサエン酸の脳蓄積性の高いリン脂質組成物 | |
FR2929515A1 (fr) | Utilisation d'acides gras comprenant un diene conjugue n-5cis, n-7trans ou un triene conjugue n-5cis, n-7trans, n-9cis en tant que medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210524 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220214 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220214 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220222 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220314 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220315 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220513 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230815 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231002 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7360793 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |